Allos Therapeutics Inc. said that sales of the lymphoma drug Folotyn drove revenue in the fourth quarter and it will cut 13 percent of its staff. The company said it expects to report revenue of $11.7 million, which tops Wall Street estimates.
Genzyme Corp. said that it expects to report revenue growth in the fourth quarter, but the preliminary results fell short of expectations. The drugmaker also trimmed its outlook for 2011 as it continues recovering from manufacturing problems.
Watson Pharmaceuticals Inc. said Wednesday its 2010 results were about equal to its expectations. The company said its earnings will be at the midpoint of its estimated range of $3.37 to $3.45 per share.
Oregon Attorney General John Kroger has sued Johnson & Johnson and two subsidiaries, claiming consumers were exposed to defective supplies of Motrin by a delay in public disclosure of a recall.
Drugmaker Eli Lilly and Co. Inc. said a panel of federal health advisers voted against an experimental treatment designed to aid digestion in patients with cystic fibrosis and other diseases that affect the pancreas.
The MoFlo Astrios next-generation cell sorter from Beckman Coulter, Inc. leverages the stable fluidic design of the original MoFlo and the electronic processing of the MoFlo XDP.
Carl Zeiss introduced a new generation of ergonomic and compact tissue culture microscopes with its Primo Vert Monitor. The traditional eyepiece has been replaced with an integrated digital camera and LCD display.
Protein analysis has quickly become as integral a component of the drug discovery process as genomics. The examination of protein expression levels and post-translational modifications helps identify new drug targets.
For decades, researchers have used Western blotting to confirm the presence of a target protein in a complex sample. After gel electrophoresis, proteins are transferred to a membrane and interrogated with antibodies.
Western blotting involves the transfer of proteins from a gel matrix to a membrane following protein electrophoresis. This process serves as a bridge between protein separation and identification.
QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient’s genomic profile.
Genzyme Corp. said that it expects to report adjusted profit and revenue growth in the fourth quarter, but the preliminary results fell short of Wall Street expectations.
Researchers have discovered a method for more precise identification of individuals who should undergo testing for genetic mutations of the tumor suppressor gene PTEN, which associates with a variety of conditions including several types of cancers.
UCLA researchers have found that a protein that plays an important role in some antioxidant therapies may not be as effective due to additional mechanisms that cause it to promote atherosclerosis, or clogging of the arteries.